A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2017.10.018
Abstract: AIMS To assess the efficacy and safety of once-weekly omarigliptin as monotherapy in people with type 2 diabetes mellitus (T2DM). METHODS People with T2DM not on glucose-lowering medications, or who were washed off monotherapy or… read more here.
Keywords: efficacy safety; group; monotherapy; omarigliptin ... See more keywords
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1335637
Abstract: Abstract Objective: To examine the efficacy and safety of the once-weekly (q.w.) dipeptidyl peptidase-4 inhibitor, omarigliptin, in patients with type 2 diabetes (T2DM) and inadequate glycemic control on metformin monotherapy. Methods: In a randomized, double-blind… read more here.
Keywords: efficacy safety; safety weekly; omarigliptin; weekly dipeptidyl ... See more keywords